SCHEMBL12873154

CC[C@H](C)[C@H](NC(=O)C(C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)C(CC(C)C)NC(=O)[C@@H](NC(=O)C(CCCCN)NNC(C)(C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)C(=O)C(=O)[C@H](Cc1ccccc1)NCNC(CC(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NC(CO)C(=O)N[C@@H](CO)C(=O)NC(C(=O)N[C@@H](CC(=O)O)C(=O)C(=O)[C@H](CO)NNC(CCC(=O)O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)C(=O)[C@@H](NC(=O)C(C)(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C

nearest known ligand 0.67

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	GLP1R	P43220	18/20	0.67

▸	NR3C1	P04150	2/20	0.60

▸	CCKBR	P32239	1/20	0.60

▸	ECE1	P42892	1/20	0.59

▸	MUS81	Q96NY9	1/20	0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL15024692	0.99	GLP1R (0.67)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL2752275	0.95	GLP1R (0.70)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL10083215	0.92	GLP1R (0.70)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL6123960	0.92	GLP1R (0.69)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL15086005	0.89	GLP1R (0.67)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL14769532	0.88	GLP1R (0.67)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL12393243	0.88	GLP1R (0.70)	GLP1RNR3C1
SCHEMBL2759455	0.88	NR3C1 (0.70)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL2742706	0.88	NR3C1 (0.70)	GLP1RNR3C1CCKBRECE1MUS81
SCHEMBL5959058	0.87	GLP1R (0.68)	GLP1RNR3C1CCKBRECE1MUS81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20110046185-A1	Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof	SANOFI-AVENTIS (FR)	2011-02-24	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110046185-A1	Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof	PGC, LIPC, CEL	GLP1R 33/4885NR3C1 550/4885CCKBR 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.